GSK · Pharma and healthcare · one day
GSK (GSK): news on Wednesday 4 November 2026
News from the 24 hours to Wednesday morning, 4 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was led by Canadian approval and priority review of GSK's hepatitis B drug bepirovirsen, plus an FDA approval for Benlysta and a proteomics research partnership. Share price weakness, a negative JP Morgan rating and softer vaccine sales tempered the positive tone.
What drove it
- hepatitis B drug approval
- Alamar research partnership
- share price weakness
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Thu 29 Oct | −6.3 | 77 |
| Fri 30 Oct | −3.7 | 21 |
| Sat 31 Oct | +4.0 | 12 |
| Mon 2 Nov | +8.0 | 3 |
| Tue 3 Nov | +2.7 | 6 |
| Wed 4 Nov | +5.0 | 14 |
6 stories · 14 headlines · strongest first
Pharma and healthcare on 4 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Alamar Biosciences and GSK proteomics study +4.67 headlines today · GSK and Alamar Biosciences are working together on a proteomic study involving 60,000 samples. | ||
| +5.0 | Same collaboration framed as advancing personalised medicine | |
| +5.0 | GSK is partner in a large research collaboration on disease biology | |
| +4.7 | GSK named partner in sizeable biomarker research project | |
| +4.5 | Same research tie-up, modestly positive for GSK's pipeline science | |
| +4.5 | Same research tie-up, modestly positive for GSK's pipeline science | |
| +4.5 | Same research tie-up, modestly positive for GSK's pipeline science | |
| +4.3 | Same collaboration covering several disease areas | |
| Hibsago approved in Canada; priority review for bepirovirsen +10.02 headlines today · Canada approved Hibsago for chronic hepatitis B and granted priority review for a submission. | ||
| +10.0 | Approval of new hepatitis B therapy, a significant milestone | |
| +10.0 | Fast-track regulatory review for promising hepatitis B drug in Canada | |
| GSK shares slip despite Q3 beat −1.32 headlines today · Articles discuss why GSK shares fell even though results topped expectations, with specialty medicines ahead and vaccines softer. | ||
| −3.3 | Shares fell even though quarterly results exceeded expectations | |
| +0.8 | Specialty drugs strong but vaccine sales softer, mixed picture | |
| GlaxoSmithKline LLC receives FDA approval for Benlysta +7.51 headline today · An FDA approval for Benlysta was issued to GlaxoSmithKline LLC. | ||
| +7.5 | Regulatory clearance for an existing GSK lupus medicine | |
| GSK shares support level and weak momentum −6.71 headline today · A piece asks whether GSK will hold above support amid selling pressure. | ||
| −6.7 | Technical weakness and selling pressure around share price support | |
| JP Morgan gives GSK a Sell rating −5.81 headline today · JP Morgan gave GSK a Sell rating. | ||
| −5.8 | Major broker holds negative rating on the shares | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.